Tuesday, February 8, 2022

Endeavor BioMedicines Gains $101M More For Precision Medicine

San Diego-based Endeavor BioMedicines, a clinical-stage biotechnology company focused on oncology and fibrosis, says it has raised $101M in its Series B funding round. The funding was led by Ally Bridge Group and Avidity Partners, and also included Perceptive Advisors, Piper Heartland Healthcare Capital, Revelation Partners, plus funds managed by Tekla Capital Management LLC, and funds and accounts advised by T. Rowe Price Associates, Inc, plus existing investors Omega Funds and Longitude Capital. The company said the funding will help advance drug candidates targeting drivers of such diseases as cancer and idiopathic pulmonary fibrosis (IPF).